---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-295465"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2021-10-08T23:59:59+00:00"
generated_at: "2026-06-28T21:46:28.222916+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Vanda's Corporate Affairs & Communications Officer Aranthan Jones II resigns, effective Oct 26, 2021

## Summary
- Aranthan 'AJ' Jones II resigns as Corporate Affairs and Communications Officer, effective October 26, 2021.
- Jones is leaving to join a U.S.-based publicly traded company outside the biopharmaceutical sector.
- No successor has been announced at this time.

## SEC filing metadata
- accession: 0001193125-21-295465
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2021-10-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000119312521295465/0001193125-21-295465-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000119312521295465/d238861d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-295465
- JSON: https://secwatch.observer/filing/0001193125-21-295465.json
- Plain text: https://secwatch.observer/filing/0001193125-21-295465.txt

## Key facts
- Executive change
  Aranthan Jones II resigned as Corporate Affairs and Communications Officer at Vanda Pharmaceuticals Inc..
  - Action: resigned
  - Role: Corporate Affairs and Communications Officer
  source text: On October 6, 2021, Aranthan “AJ” Jones II notified Vanda Pharmaceuticals Inc. of his resignation as the Company’s Corporate Affairs and Communications Officer, effective as of October 26, 2021, in order to join a U.S.-based, publicly traded company outside of the biopharmaceutical sector.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1347178/000119312521295465/0001193125-21-295465-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.